On May 21, 2025, Thermo Fisher Scientific’s board approved a performance-based stock grant valued at approximately $60 million for CEO Marc Casper, incentivizing long-term leadership and shareholder returns through May 2030. This decision follows significant revenue growth under his leadership, which has seen annual revenue rise from $10 billion to $43 billion and total shareholder return exceed 800%.